3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Psoriasis
1
Lymphoma, Follicular
1
Interventions
tofacitinib
7
Etanercept
4
deucravacitinib
2
Methotrexate
2
Adalimumab
2
sotrastaurin
1
sodium luminolate
1
secukinumab
1
ixekizumab
1
calcipotriene
1
baricitinib
1
apremilast
1
abrocitinib
1
Anti-Infective Agents, Local
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Psoriasis
×
Anti-Infective Agents, Local
×
Clear all
NCT01313221
2017-03-15
REFINE
Amgen
Phase 3
Completed
310 enrolled
32 charts